Residency · Residency · Internal Medicine

VTE Prophylaxis in the Hospitalized Patient

Introduction

Venous thromboembolism (VTE), encompassing deep vein thrombosis (DVT) and pulmonary embolism (PE), is a leading cause of preventable death in hospitalized patients. Despite strong evidence supporting thromboprophylaxis, VTE prevention remains inconsistently applied. Every internist must systematically assess VTE risk, select appropriate prophylaxis, and balance the competing risk of bleeding.

Epidemiology

• Hospital-acquired VTE accounts for approximately 50-60% of all VTE events in the United States
• Without prophylaxis, VTE occurs in 10-40% of medical and surgical inpatients
• PE is the most common preventable cause of hospital death
• VTE risk persists for weeks after discharge, especially following surgery or acute medical illness

Risk Assessment

VTE Risk Factors

• Patient factors: age > 40, obesity (BMI > 30), prior VTE, active malignancy, thrombophilia
• Medical conditions: heart failure, acute respiratory failure, stroke with limb paresis, sepsis, inflammatory bowel disease
• Immobility: bedrest > 3 days, paralysis, critical illness
• Iatrogenic: central venous catheters, surgery, estrogen therapy, mechanical ventilation

Risk Assessment Models

• Padua Prediction Score (medical patients): score >= 4 indicates high VTE risk warranting pharmacologic prophylaxis

• Caprini Score (surgical patients): stratifies VTE risk from very low to high
• IMPROVE VTE score: validated for acutely ill medical patients

Bleeding Risk Assessment

• IMPROVE Bleeding Score: assesses bleeding risk to guide prophylaxis decisions
• Risk factors for bleeding: active GI ulcer, bleeding within 3 months, platelet count < 50,000, hepatic/renal failure, ICU/CCU stay, central venous catheter, rheumatic disease, active cancer, age >= 85
• High bleeding risk does not automatically preclude prophylaxis; consider mechanical prophylaxis

Pharmacologic Prophylaxis

Options for Medical Patients

• Low-molecular-weight heparin (LMWH): enoxaparin 40 mg SQ daily (preferred in most patients)
• Unfractionated heparin (UFH): 5,000 units SQ every 8-12 hours (preferred in renal insufficiency, CrCl < 30)
• Fondaparinux: 2.5 mg SQ daily (alternative for HIT history)
• Duration: throughout the period of immobility or acute illness; typically until discharge
• Extended post-discharge prophylaxis is NOT routinely recommended for medical patients (MARINER, APEX trials showed modest benefit but increased bleeding)

Options for Surgical Patients

• LMWH or UFH starting preoperatively or within 12-24 hours postoperatively
• Extended prophylaxis post-discharge: recommended for major orthopedic surgery (total hip/knee, hip fracture) for up to 35 days
• Major abdominal/pelvic surgery for cancer: extended prophylaxis for 4 weeks (ENOXACAN II)
• Direct oral anticoagulants (DOACs): rivaroxaban and apixaban approved for extended prophylaxis after hip/knee replacement

Special Populations

• Renal insufficiency (CrCl < 30 mL/min): use UFH; if LMWH used, dose-adjust and monitor anti-Xa levels
• Obesity (BMI > 40 or weight > 120 kg): consider higher-dose LMWH (enoxaparin 40 mg SQ BID)
• Heparin-induced thrombocytopenia (HIT): contraindication to all heparins; use fondaparinux or argatroban
• Pregnancy: LMWH is the agent of choice; UFH is an alternative
• Active bleeding or very high bleeding risk: mechanical prophylaxis only; reassess daily

Mechanical Prophylaxis

• Intermittent pneumatic compression (IPC) devices: first-line when pharmacologic prophylaxis is contraindicated
• Graduated compression stockings (GCS): less effective than IPC; contraindicated in peripheral arterial disease
• Mechanical prophylaxis alone is inferior to pharmacologic prophylaxis and should be used only when anticoagulation is contraindicated
• Combination mechanical + pharmacologic may be considered in very high-risk patients (e.g., major trauma)

Common Clinical Scenarios

Acute Ischemic Stroke

• Pharmacologic prophylaxis with LMWH or UFH; timing depends on hemorrhagic transformation risk
• IPC devices should be initiated immediately on admission
• Early mobilization when safe

Active Bleeding

• Mechanical prophylaxis with IPC
• Reassess daily for transition to pharmacologic prophylaxis once bleeding is controlled
• Do not reflexively withhold pharmacologic prophylaxis indefinitely

Critical Illness

• Most ICU patients warrant pharmacologic prophylaxis
• UFH preferred if procedures or renal replacement therapy anticipated
• LMWH may be superior to UFH in critically ill patients (PROTECT trial)

COVID-19 Hospitalization

• Standard-dose thromboprophylaxis for non-critically ill patients
• Therapeutic-dose anticoagulation (ACTIV-4a/ATTACC): improved outcomes in non-critically ill patients but not in ICU patients

Quality Improvement and Implementation

• VTE prophylaxis should be assessed on every patient at admission and daily thereafter
• Electronic health record alerts and order sets improve compliance
• VTE is a CMS hospital-acquired condition; lack of prophylaxis is considered a preventable harm
• Nursing-driven protocols for IPC compliance (devices must be on whenever in bed)
• Risk assessment tools embedded in admission order sets

Key Clinical Pearls

• Assess VTE risk on every patient at admission; use the Padua score for medical patients
• LMWH is preferred over UFH in most medical patients; use UFH for CrCl < 30
• Mechanical prophylaxis alone is only acceptable when pharmacologic prophylaxis is truly contraindicated
• Extended post-discharge prophylaxis is routine after major orthopedic and cancer surgery but not standard for medical patients
• Reassess prophylaxis daily; bleeding risk and VTE risk change throughout the hospitalization

References

1. Kahn SR, Lim W, Dunn AS, et al. Prevention of VTE in nonsurgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: ACCP evidence-based clinical practice guidelines. Chest. 2012;141(2 Suppl):e195S-e226S.
2. Schunemann HJ, Cushman M, Burnett AE, et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: prophylaxis for hospitalized and nonhospitalized medical patients. Blood Adv. 2018;2(22):3198-3225.
3. PROTECT Investigators. Dalteparin versus unfractionated heparin in critically ill patients. N Engl J Med. 2011;364(14):1305-1314.
4. ATTACC Investigators. Therapeutic anticoagulation with heparin in noncritically ill patients with COVID-19. N Engl J Med. 2021;385(9):790-802.

For the intern

At 3am, assess every new admission for venous thromboembolism (VTE) risk using the Padua score—if ≥4 points, start pharmacologic prophylaxis immediately unless active bleeding exists. For most medical patients, order enoxaparin 40 mg subcutaneously daily; switch to unfractionated heparin (UFH) 5,000 units every 8 hours if creatinine clearance is below 30 mL/min. If anticoagulation is contraindicated due to active bleeding or very high bleeding risk, place intermittent pneumatic compression (IPC) devices and reassess daily. Everything else—extended prophylaxis decisions, switching agents for convenience, or complex risk scoring—can wait for morning rounds.

Common pitfalls

• Forgetting renal dosing: Low-molecular-weight heparin (LMWH) accumulates in renal failure. Always use UFH when creatinine clearance is below 30 mL/min, or you risk bleeding complications.

• Overestimating bleeding risk: Active gastrointestinal ulcer or recent hemorrhage warrants mechanical prophylaxis only, but thrombocytopenia above 50,000 or mild liver disease does not automatically contraindicate pharmacologic prophylaxis. Reassess daily rather than reflexively withholding anticoagulation for the entire hospitalization.

• Inadequate mechanical prophylaxis: IPC devices only work when actually on the patient's legs. Ensure nursing compliance and document that devices are functioning—this is a hospital-acquired condition that Centers for Medicare and Medicaid Services (CMS) tracks.

• Ignoring obesity: Patients over 120 kg may need higher doses (enoxaparin 40 mg twice daily instead of once daily) for adequate prophylaxis.

Make it stick

You're a new intern admitting a 78-year-old female for pneumonia, found altered at home by her family. She has a history of atrial fibrillation on apixaban, recent fall with a minor head contusion (non-hemorrhagic on CT), and a new cancer diagnosis a month ago. She’s too weak to ambulate. You calculate her Padua score: Age ≥ 70 (+1), reduced mobility (+3), active cancer (+3) = 7. High risk. Bleeding risk? Recent head contusion, on apixaban. This patient needs thromboprophylaxis, but with caution. You hold the apixaban (per protocol for altered mental status and recent head injury), order intermittent pneumatic compression devices, and page the senior resident to discuss starting unfractionated heparin at a reduced dose or waiting, balancing her high VTE risk against potential for bleeding in a vulnerable patient.

If you remember one thing

Always assess venous thromboembolism risk at admission using a validated score like Padua, and initiate appropriate prophylaxis promptly. When pharmacologic prophylaxis is contraindicated, mechanical prophylaxis is essential but requires diligent daily reassessment for transition to anticoagulation.

Read this lecture as Markdown